1. Home
  2. RUM vs MLYS Comparison

RUM vs MLYS Comparison

Compare RUM & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rumble Inc.

RUM

Rumble Inc.

HOLD

Current Price

$4.98

Market Cap

2.0B

Sector

Technology

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$26.97

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUM
MLYS
Founded
2013
2019
Country
United States
United States
Employees
135
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.2B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
RUM
MLYS
Price
$4.98
$26.97
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$10.00
$48.67
AVG Volume (30 Days)
1.8M
1.3M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$209.98
N/A
Revenue Next Year
$40.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.62
$10.44
52 Week High
$10.99
$47.65

Technical Indicators

Market Signals
Indicator
RUM
MLYS
Relative Strength Index (RSI) 42.74 53.31
Support Level $4.67 $26.85
Resistance Level $7.02 $30.53
Average True Range (ATR) 0.23 1.50
MACD -0.00 0.48
Stochastic Oscillator 40.47 68.16

Price Performance

Historical Comparison
RUM
MLYS

About RUM Rumble Inc.

Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: